



## NOTIFICATION

### *Addendum*

The following communication, dated , is being circulated at the request of the delegation of Brazil.

**Title:** Draft Resolution number 760, December 27th, 2019.

Reason for Addendum:	
<input type="checkbox"/>	Comment period changed - date:
<input type="checkbox"/>	Notified measure adopted - date:
<input type="checkbox"/>	Notified measure published - date:
<input type="checkbox"/>	Notified measure enters into force - date:
<input type="checkbox"/>	Text of final measure available from <sup>1</sup> :
<input type="checkbox"/>	Notified measure withdrawn or revoked - date: Relevant symbol if measure re-notified:
<input checked="" type="checkbox"/>	Content or scope of notified measure changed and text available from <sup>1</sup> : <a href="https://antigo.anvisa.gov.br/documents/10181/5740831/RDC_931_2024_.pdf/42c43a0e-99cd-4114-9fe1-d5b6421a68d1">https://antigo.anvisa.gov.br/documents/10181/5740831/RDC_931_2024_.pdf/42c43a0e-99cd-4114-9fe1-d5b6421a68d1</a> New deadline for comments (if applicable):
<input type="checkbox"/>	Interpretive guidance issued and text available from <sup>1</sup> :
<input type="checkbox"/>	Other:

**Description:** Resolution 742, 10 August 2022 - previously notified through G/TBT/N/BRA/955/Add.1 - which establishes the minimal technical requirements for relative bioavailability and bioequivalence studies that supports dossier of consent for clinical research, market

authorization or post-market authorization of medicines, in the terms of this resolution, was change by Resolution 931, 09 October 2024.

The final text is available only in Portuguese and can be downloaded at:

[https://antigo.anvisa.gov.br/documents/10181/5740831/RDC\\_931\\_2024\\_.pdf/42c43a0e-99cd-4114-9fe1-d5b6421a68d1](https://antigo.anvisa.gov.br/documents/10181/5740831/RDC_931_2024_.pdf/42c43a0e-99cd-4114-9fe1-d5b6421a68d1)

<sup>1</sup> This information can be provided by including a website address, a pdf attachment, or other information on where the text of the final/modified measure and/or interpretive guidance can be obtained.